Bridgeway Capital Management Inc. boosted its position in Cidara Therapeutics Inc (NASDAQ:CDTX) by 90.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 179,000 shares of the biotechnology company’s stock after purchasing an additional 85,000 shares during the period. Bridgeway Capital Management Inc. owned about 0.65% of Cidara Therapeutics worth $788,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of CDTX. Acadian Asset Management LLC lifted its stake in Cidara Therapeutics by 113.6% in the second quarter. Acadian Asset Management LLC now owns 86,515 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 46,019 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Cidara Therapeutics by 88.5% in the third quarter. JPMorgan Chase & Co. now owns 149,050 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 69,998 shares during the last quarter. West Family Investments Inc. lifted its stake in Cidara Therapeutics by 53.9% in the second quarter. West Family Investments Inc. now owns 153,874 shares of the biotechnology company’s stock valued at $800,000 after purchasing an additional 53,874 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Cidara Therapeutics by 144.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 168,622 shares of the biotechnology company’s stock valued at $877,000 after purchasing an additional 99,627 shares during the last quarter. Finally, Raymond James & Associates raised its holdings in Cidara Therapeutics by 104.1% during the 2nd quarter. Raymond James & Associates now owns 195,878 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 99,927 shares during the period. Institutional investors and hedge funds own 65.20% of the company’s stock.
Shares of CDTX stock opened at $3.33 on Friday. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.13. Cidara Therapeutics Inc has a 1 year low of $3.05 and a 1 year high of $8.55. The firm has a market cap of $101.57 million, a price-to-earnings ratio of -1.05 and a beta of 1.82.
Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.11. As a group, sell-side analysts expect that Cidara Therapeutics Inc will post -2.27 EPS for the current fiscal year.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Tuesday, November 13th. Cantor Fitzgerald set a $15.00 target price on shares of Cidara Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $10.38.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/08/cidara-therapeutics-inc-cdtx-shares-bought-by-bridgeway-capital-management-inc.html.
Cidara Therapeutics Profile
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Read More: Average Daily Trade Volume – What You Need to Know
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.